Time is (still) of the essence: Quantifying the impact of emergency meningitis vaccination response in Katsina State, Nigeria

International Health

Volumn 6, Issue 4, 2014, Pages 282-290

  Ferrari, Matthew J ^a   Fermon, Florence ^b   Nackers, Fabienne ^c   Llosa, Augusto ^c   Magone, Claire ^c   Grais, Rebecca F ^c  

^a PENNSYLVANIA STATE UNIVERSITY   (United States)

^b EPICENTRE   (France)

^c MÉDECINS SANS FRONTIÈRES   (Switzerland)

Author keywords

Meningitis surveillance; Neisseria meningitidis serogroup A; Nigeria; Polysaccharide vaccine; Vaccination outbreak response

Indexed keywords

MENINGITIS VACCINE; POLYSACCHARIDE VACCINE; BACTERIAL POLYSACCHARIDE; BACTERIAL VACCINE; MENINGOCOCCUS VACCINE;

ADOLESCENT; ADULT; ARTICLE; CHILD; EPIDEMIC MENINGITIS; FEVER; HUMAN; INFECTION CONTROL; MAJOR CLINICAL STUDY; MASS IMMUNIZATION; NIGERIA; PRIORITY JOURNAL; STIFF NECK; TREATMENT RESPONSE; VACCINATION; DISEASE OUTBREAKS; EPIDEMIOLOGY; FEMALE; IMMUNOLOGY; MALE; MENINGITIS, MENINGOCOCCAL; ORGANIZATION AND MANAGEMENT; PRESCHOOL CHILD; YOUNG ADULT;

ADOLESCENT; ADULT; BACTERIAL VACCINES; CHILD; CHILD, PRESCHOOL; DISEASE OUTBREAKS; FEMALE; HUMANS; MALE; MASS VACCINATION; MENINGITIS, MENINGOCOCCAL; MENINGOCOCCAL VACCINES; NIGERIA; POLYSACCHARIDES, BACTERIAL; YOUNG ADULT;

EID: 84925304550     PISSN: 18763413     EISSN: 18763405     Source Type: Journal    
DOI: 10.1093/inthealth/ihu062     Document Type: Article

References (27)

1. LaForce FM, Ravenscroft N, Djingarey M, Viviani S. Epidemic meningitis due to Group A Neisseriameningitidis in the African meningitis belt: a persistent problem with an imminent solution. Vaccine 2009;27(Suppl. 2):B13-9.
2. Mueller JE, Gessner BD. A hypothetical explanatory model for meningococcal meningitis in the African meningitis belt. Int J Infect Dis 2010;14:e553-9.
3. Trotter CL, Gay NJ, Edmunds WJ. Dynamic models of meningococcal carriage, disease, and the impact of serogroup C conjugate vaccination. Am J Epidemiol 2005;162:89-100.
4. Broutin H, Philippon S, de Magny GC et al. Comparative study of meningitis dynamics across nine African countries: a global perspective. Int J Health Geogr 2007;6:6-29.
5. Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine 2009;27(Suppl.2):B51-63.
6. Kieny MP, LaForce EM. The promise of conjugate vaccines for Africa. Vaccine 2007;25(Suppl. 1):A108-10.
7. WHO. WHO strategy for prevention and control of meningococcal disease in Africa. Geneva: WHO; 2001.
8. Leake JAD, Kone ML, Yada AA et al. Early detection and response to meningococcal disease epidemics in sub-Saharan Africa: appraisal of the WHO strategy. Bull WHO 2002;80:342-9.
9. Pinner RW, Onyango F, Perkins BA et al. Epidemic meningococcal disease in Nairobi, Kenya, 1989. J Infect Dis 1992;166:359-64.
10. Lewis R, Nathan N, Diarra L et al. Timely detection of meningococcal meningitis epidemics in Africa. Lancet 2001;358:287-93.
11. Woods CW, Armstrong G, Sackey SO et al. Emergency vaccination against epidemic meningitis in Ghana: implications for the control of meningococcal disease in West Africa. Lancet 2000;355:30-33.
12. Grais RF, Conlan AJK, Ferrari MJ et al. Time is of the essence: exploring a measles outbreak response vaccination in Niamey, Niger. J RSoc Interface 2008;5:67-74.
13. Trotter C. Epidemiology of meningococcal disease and the impact of vaccination in Europe. Wurzburg, Germany: 58th Annual Conference, German Society for Hygiene and Microbiology (DGHM); 2006.
14. WHO. Meningitis in Chad, Niger and Nigeria: 2009 epidemic season. Wkly Epidemiol Rec 2010;85:57-68.
15. Kristiansen PA, Diomande F, Wei SC et al. Baseline meningococcal carriage in Burkina Faso before the Introduction of a meningococcal serogroup A conjugate vaccine. Clin Vaccine Immunol 2011;18:435-43.
16. Stephens DS. Biology and pathogenesis of the evolutionarily successful, obligate human bacterium Neisseria meningitidis. Vaccine 2009;27(Suppl.2):B71-7.
17. Greenwood BM, Hassanking M, Whittle HC. Prevention of secondary cases of meningococcal disease in household contacts by vaccination. Br Med J 1978;1:1317-9.
18. Breto C, He DH, Ionides EL, King AA. Time series analysis via mechanistic models. Ann Appl Stat 2009;3:319-48.
19. Ferrari MJ, Grais RF, Bharti N et al. The dynamics of measles in sub-Saharan Africa. Nature 2008;451:679-84.
20. Clark J, Bjornstad ON. Population inference from messy data: errors, missing values and hidden states. Ecology 2004;85:3140-50.
21. Ionides EL, Breto C, King AA. Inference for nonlinear dynamical systems. Proc Natl Acad Sci U S A 2006;103:18438-43.
22. Jandarov R, Haran M, Ferrari M. A compartmental model for meningitis: separating transmission from climate effects on disease incidence. J Agr Biol Envir Stat 2012;17:395-416.
23. Trotter CL, Maiden MCJ. Meningococcal vaccines and herd immunity: lessons learned from serogroup C conjugate vaccination programs. Expert Rev Vaccines 2009;8:851-61.
24. Maiden MCJ, Stuart JM. Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination. Lancet 2002;359:1829-30.
25. Moore MR, Hyde TB, Hennessy TW et al. Impact of a conjugate vaccine on community-wide carriage of nonsusceptible Streptococcus pneumoniae in Alaska. J Infect Dis 2004;190:2031-8.
26. Ramsay ME, Andrews NJ, Trotter CL et al. Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis. Br Med J 2003;326:365-6.
27. Vestrheim DF, Hoiby EA, Aaberge IS, Caugant DA. Impact of a pneumococcal conjugate vaccination program on carriage among children in Norway. Clin Vaccine Immunol 2010;17:325-34.